Validation of Italian cognitive assessment scales for elderly patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to translate, adapt, and validate functional and behavioral scales for diagnosing neurodegenerative diseases in Italian-speaking populations. It focuses on tools such as the Basic Activities of Daily Living (BADL), Instrumental Activities of Daily Living (IADL), Everyday Cognition questionnaire (ECog), and Neuropsychiatric Inventory Questionnaire (NPI-Q). The study will also evaluate the psychometric properties of a modified Italian version of the Functional Activities Questionnaire (M-FAQ). By ensuring these tools are culturally relevant and scientifically validated, the study seeks to improve diagnostic accuracy for conditions like Mild Cognitive Impairment and Mild Dementia.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 60 years;
* Availability of an informant/caregiver, able to judge their functional abilities.

For neurologically unimpaired elderly:

\- Normal performance on the Mini Mental State Examination (Folstein et al. 1975; Foderaro et al., 2022).

For clinical groups: Conditions consistent with:

* Subjective Cognitive Decline (Jessen et al., 2014)
* Mild Cognitive Impairment (Winblad et al., 2004)
* Mild Major Neurocognitive Disorder according (DSM-5-TR, APA, 2022).

Exclusion Criteria:

* Refusal or inability to sign informed consent;
* For the clinical groups: other neurological or psychiatric conditions that may explain the presence of cognitive difficulties.

Where it's running

• Casa di Cura Igea
  Milan, Michigan, Italy Recruiting

Study contacts

• Principal investigator: Sabrina Guzzetti — Casa di Cura IGEA, Milan, Italy
• Study coordinator: Sabrina Guzzetti, Psychologist
• Email: s.guzzetti@casadicurigea.it
• Phone: +390248593315

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Aging Brain Health Initiative in Fujian

  This observational study will follow about 3,000 older adults in Fujian to see how Alzheimer's-related changes develop and to test new digital tests, biomarkers, and imaging tools for early diagnosis.

  Recruiting at 4 sites Fujian Medical University Union Hospital · Fushun, Fujian and 3 other locations · NCT07891429

• Digital tools to predict Alzheimer's biology from risk factors

  This study tests a digital, AI-based tool that analyzes modifiable and non-modifiable risk factors to see if it can predict biological changes linked to Alzheimer's disease in adults with MCI or SCD.

  Recruiting at 2 sites IRCCS Centro San Giovanni di Dio Fatebenefratelli · Brescia, BS and 1 other locations · NCT07731191

• Online positive psychology program to support thinking and brain health in early memory changes

  This study will test whether an online positive psychology program can improve thinking, brain function, and wellbeing in older adults with early memory problems (Subjective Cognitive Decline or Mild Cognitive Impairment).

  Recruiting Aristotle University Of Thessaloniki · Thessaloniki · NCT07289061

• Personalized digital training for cognitive fitness in people with mild cognitive impairment

  This study tests whether a personalized home-based digital program (RICORDO) helps people aged 50 and older with mild cognitive impairment or subjective cognitive decline manage their health and daily life better than a paper-and-video education program.

  Recruiting at 2 sites University of Modena and Reggio Emilia · Modena, Reggio Nell'Emilia (RE) and 1 other locations · NCT07286448

• NPC-1 (parthenolide and ipriflavone) for Alzheimer's blood biomarkers

  This trial will test whether taking NPC-1 (a combination of parthenolide and ipriflavone) is safe, well tolerated, and changes blood tests linked to Alzheimer's in adults 55+ with subjective cognitive decline, mild cognitive impairment, or mild Alzheimer's who have biomarker evidence of disease.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts · NCT07236190

• InRAD international registry for Alzheimer's disease and related dementias

  This project will collect routine medical information over time to see how Alzheimer's disease, mild cognitive impairment, and related dementias progress and how current treatments are tolerated in adults.

  Recruiting at 23 sites Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Melbourne and 22 other locations · NCT07213700

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.